Related Experiment Video
Updated: May 15, 2025

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children
1Department of Pediatrics, Division of Pediatric Cardiology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Insights
Pediatric pulmonary hypertension (PH) causes right ventricular failure (RVF) due to pulmonary vascular changes, often linked to congenital heart disease (CHD). New treatments are needed to reverse RV remodeling and improve outcomes in children.
Area of Science:
- Cardiology
- Pediatric Pulmonology
- Cardiovascular Research
Background:
- Pulmonary hypertension (PH) is a progressive disorder causing right ventricular strain and failure (RVF).
- Pediatric PH management differs from adults due to congenital heart disease (CHD) prevalence and developmental factors.
- CHD, especially unrepaired shunts, is a primary driver of PH in children, leading to vascular remodeling.
Purpose of the Study:
- To analyze the mechanisms of RVF in PH, considering adult and pediatric specificities.
- To review current pharmacological and interventional treatments for pediatric PH.
- To emphasize the need for novel therapies targeting RV remodeling in children.
Main Methods:
- Comprehensive analysis of RVF mechanisms in PH.
- Incorporation of adult clinical studies and experimental models.
- Highlighting unique pediatric considerations in PH and RVF.
Main Results:
- PH leads to increased pulmonary vascular resistance (PVR), RV strain, and RVF.
- Elevated pulmonary blood flow from left-to-right shunts can cause progressive vascular remodeling.
- Current treatments focus on reducing PVR, but RV function improvement is challenging.
Conclusions:
- Pediatric PH requires tailored management due to CHD and developmental dynamics.
- Novel therapeutic strategies are essential to directly reverse RV remodeling.
- Further research into disease-modifying treatments is crucial for improving long-term outcomes in children with PH.
Abstract:
Pulmonary hypertension (PH) is a progressive disorder characterized by obstructive changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance (PVR), right ventricular (RV) strain, and eventual RV failure (RVF). Despite advancements in medical therapy, PH remains associated with significant morbidity and mortality, particularly in children. RVF is a clinical syndrome resulting from complex structural and functional remodeling of the right heart, leading to inadequate pulmonary circulation, reduced cardiac output, and elevated venous pressure. Management paradigms for pediatric PH diverge significantly from those in adults, particularly due to the predominance of congenital heart disease (CHD) and the dynamic nature of pediatric cardiovascular and pulmonary development. CHD remains a principal driver of PH in children, and its associated pathophysiology demands a nuanced approach. In patients with unrepaired left-to-right shunts, elevated pulmonary blood flow can lead to progressive pulmonary vascular remodeling and increased PVR. The postoperative persistence or progression of PH may occur if irreversible vascular changes have already developed. Current PH treatments primarily focus on reducing PVR, yet distinguishing between therapeutic approaches that target the pulmonary vasculature and those aimed at improving RV function remain challenging. In pediatric patients with progressive PH despite optimal therapy, additional targeted interventions may be necessary to mitigate RV dysfunction and disease progression. This review provides a comprehensive analysis of the mechanisms underlying RVF in PH, incorporating insights from clinical studies in adults and experimental models, while highlighting the unique considerations in children. Furthermore, it explores current pharmacological and interventional treatment strategies, emphasizing the need for novel therapeutic approaches aimed at directly reversing RV remodeling. Given the complexities of RV adaptation in pediatric PH, further research into disease-modifying treatments and innovative interventions is crucial to improving long-term outcomes in affected children.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...

